Loading patent…
AssigneesUNM Rainforest Innovations, The United States Government as represented by the Department of Veterans Affairs
InventorsHenry C. Lin, Nancy L. Kanagy, Aleksandr Birg, Sudha Singh, Cristina N. Coffman
Estimating the term…
The present invention is directed to compositions which comprise at least two components comprising a magnesium compound and glutamine, often three components, a high bioavailability magnesium salt or chelate, a low bioavailability magnesium salt or chelate and glutamine (often as a neutral species or as a zwitterionic salt). It has been discovered unexpectedly that the compositions which contain these two or three components are effective at treating/inhibiting metabolic syndrome and its symptomology, including insulin resistance, and related disease states and/or conditions. Compositions according to the present invention also inhibit/treat dysbiosis such that the gut microbiome is maintained or returns to normal.
A composition formulated in one or two parts comprising at least one magnesium compound in combination with glutamine or a pharmaceutically acceptable salt thereof wherein said magnesium compound and said glutamine or pharmaceutically acceptable salt thereof comprises in combination an effective amount for treating metabolic syndrome or a related disease state, condition or symptom thereof.
A method of treating metabolic syndrome or a related disease state, condition or symptom thereof and gut dysbiosis, comprising administering to a patient or subject in need an effective amount of at least one magnesium compound in combination with an effective amount of glutamine or a pharmaceutically acceptable salt thereof.
A method of treating a disease state and/or condition selected from the group consisting of metabolic syndrome, insulin resistance, impaired glucose metabolism, insulin resistance, dysregulation of blood pressure and dyslipidemia, cardiovascular disease, diabetes (especially diabetes II), cerebrovascular disease, fatty liver disease, non-alcoholic steatohepatitis (NASH) and fibrosis in combination with gut dysbiosis, comprising administering to a patient or subject in need an effective amount of at least one magnesium compound in combination with an effective amount of glutamine or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.